KAKEN PHARMACEUTICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,575 JPY | -2.48% |
|
+3.26% | +6.56% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company's share price in relation to its net book value makes it look relatively cheap.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +6.56% | 861M | - | ||
| +40.73% | 739B | C+ | ||
| +32.83% | 598B | B | ||
| -6.30% | 353B | C+ | ||
| +15.15% | 318B | B- | ||
| +4.05% | 285B | C+ | ||
| +15.00% | 240B | B+ | ||
| +9.78% | 210B | B- | ||
| -5.52% | 206B | A+ | ||
| +6.17% | 164B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 4521 Stock
- Ratings Kaken Pharmaceutical Co., Ltd.
